Mutation analysis reveals novel sequence variants in
for each variant confirmed the sequencing results. All variants were also present in the corresponding germline DNA. Interestingly, the sequence variants at codon 604 (c1810CϾT) and codon 613 (c1838GϾT) of exon 15 always occurred together and might represent linkage disequilibrium. The frequencies of the sequence variants in germline DNA from patients with sporadic MTC did not differ significantly from those in a race-matched control group. Although we did not find any somatic mutations of NTRK1 in sporadic MTC, the single-strand conformational polymorphism conditions reported here, together with the knowledge of the frequency of various sequence variants, may help in future mutation analyses of DNA from other neural and nonneural tissues. (J Clin Endocrinol Metab 84: 2784 -2787, 1999) M OST THYROID carcinomas derive from thyroid follicular cells, among which papillary thyroid carcinoma (PTC) is, by far, the most common type (60 -80%). The diagnosis is based on a constellation of features, such as papillary architecture, the presence of psammoma bodies, ground-glass nuclei, and indentations of the nuclear membrane (grooved nuclei), not all of which may be present in a single tumor. Although PTC metastasizes relatively early, usually by the lymphatic system, hematogenous metastasis is infrequent. The prognosis is generally considered to be good. In contrast, medullary thyroid carcinoma (MTC) derives from the parafollicular C cells and is less common (5-10%) . The histopathological pattern may vary considerably (such as classic, papillary, amyloid-rich, insular, trabecular, small-cell variants). Lymphogenous and hematogenous metastases are common clinical presentations, and the overall prognosis is worse, compared with patients having PTC. Surprisingly, despite these obvious differences, PTC and MTC have one gene in common that somehow contributes to their distinct carcinogenesis: the protooncogene RET.
In 1985, Takahashi et al. found this new transforming gene, activated by DNA rearrangement during transfection (RET) of NIH 3T3 cells (1) . RET encodes a transmembrane tyrosine kinase receptor that is expressed in neural and neuroendocrine tissues (2) . As of today, at least five types of RET rearrangements (translocations and inversions) have been found in PTC (RET/PTC1-5) (3) (4) (5) (6) (7) . The subsequent activation of RET, in this manner, seems to be restricted to PTCs (8) , although one study reports RET rearrangement in a thyroid adenoma (9) .
In 1993, RET was also found to be involved in the pathogenesis of MTC. Germline mutations of RET have been found to be associated with familial forms of MTC (FMTC, MEN 2A, MEN 2B; for review see Ref. 10) (11) (12) (13) (14) (15) . Of interest, 30 -70% of sporadic MTC harbor a somatic RET mutation (16) . In contrast to PTC, mutations found in MTC are almost exclusively missense mutations.
Another tyrosine kinase, NTRK1 (also known as TrkA), has also been found to be widely expressed in neural and nonneuronal tissues (17, 18) , and we have shown that NTRK1 is expressed in MTC (Gimm and Eng, unpublished data) . NTRK1, encoding one of the receptors for nerve growth factor, consists of at least 17 exons and is located on chromo-because of their large sizes. Some PCR products (see Table 1 ) were subjected to further digestion to get smaller fragments that are believed to be more likely to show alternate banding patterns using single-strand conformational polymorphism (SSCP) (24) . The digestion was performed according to the manufacturer's recommendation (New England Biolabs, Inc., Beverly, MA).
Before SSCP, 2 L of the resulting PCR/digestion product were added to 3 L of formamide buffer, then heated to 95 C for 10 min, and subsequently cooled on dry ice. Immediately before SSCP, the samples were quickly thawed and then run on a 10% polyacrylamide/1ϫTris-Borate-EDTA gel, except exon 14, which was electrophoresed through a 10% polyacrylamide/1ϫTris-Borate-EDTA/10% glycerol gel. Gels were run either at 100 V for 14 h at room temperature (exons 2, 4 -7, 9 -16, and 17a) or at 150 V for 16 h at 4 C (exons 3, 8a, 8b, and 17b) . Subsequent silver staining was performed as follows: 10 min in 0.5% acetic acid and 10% ethanol (fixation), 10 min in 0.1% silver nitrate (staining), 20 min in 1.5% sodium hydroxide and 0.01% sodium borohydride and 0.05% formaldehyde (development), and 10 min in 0.75% sodium carbonate (fixation).
If variant SSCP banding patterns were seen, the remaining PCR aliquot was subjected to purification and semiautomated sequencing using the above primers and dye terminator technology, as previously described (25, 26) . If sequencing revealed a sequence variant, the corresponding leucocyte DNA was examined in the same manner to determine whether the sequence variant is somatic or germline. Further, we analyzed whether the nucleotide change would create or remove the recognition site of a restriction enzyme to prove, by three different means, the existence of this variant. The frequencies of these sequence variants, in patients with MTC and in a race-matched control group, were determined. 
Results
SSCP analysis of all 16 exons of NTRK1 from 31 sporadic MTC revealed variants in five exons (exons 4, (14) (15) (16) and 17a; Fig. 1) . Sequencing revealed 1 sequence variant each in exons 4, 14, 16, and 17a , and 4 different variants in exon 15 (Table  2) . Differential restriction enzyme digestion, specific for each variant, confirmed the sequencing results. Corresponding germline DNA was examined for the presence of each of these variants, and all were also present in the germline. Interestingly, the sequence variants at codon 604 (c1810CϾT) and codon 613 (c1838GϾT) of exon 15 always occurred together. The frequencies of the sequence variants in DNA from patients with sporadic MTC did not differ significantly from those in a race-matched control group (Table 2) .
One previously described variant (27) was not detected (c1767TϾC) in this study either by SSCP or restriction analysis ( Table 2) .
Discussion
In the present study, we detected 3 previously reported polymorphisms (27) and 5 novel sequence variants in NTRK1, and we determined their frequencies in DNA from patients with sporadic MTC and a race-matched control group. One previously reported sequence variant (27) in exon 14 (c1767TϾC) could not be detected by SSCP and restriction analysis of 126 total alleles (60 MTC alleles, 66 control alleles).
We did not detect any somatic mutations of NTRK1 in tumor DNA from 31 independent patients with sporadic MTC. The absence of any somatic sequence variant of NTRK1 is somewhat surprising. Though it is obvious that highpenetrance mutations of NTRK1 are not associated with medullary thyroid tumorigenesis, it is becoming more and more evident that development of a cancer can result from an interplay of either a few high penetrance mutations in key genes or from several, or many, sequence variants of unknown significance (28). For example, overrepresentation of a rare sequence variant of RET has been observed in patients with sporadic MTC (29); this variant, together with variants in other genes, may somehow predispose to MTC in a low penetrance fashion.
Although we did not find any somatic mutations of NTRK1 in sporadic MTC, nor did we find an association with sequence variants, the SSCP conditions reported here, together with the knowledge of the frequency of various sequence variants, may help in future mutation analyses of DNA from other neural and nonneural tissues, such as squamous cell carcinoma of the esophagus, squamous cell carcinoma of the uterus, and ductal carcinoma of the breast (18) . The frequency of this polymorphism has not been determined using the restriction enzyme MaeII, but MaeII could be used in this regard. c Restriction enzyme BamHI would cut after amplification of exon 15 using the primers TRK15F-BamHI (5Ј-CCCAGCCTATCCCCTCTC-CTTTTCTGGATC-3Ј) and NTRK1-15R.
d Sequencing revealed that these two sequence variants always occur together. Medullary thyroid carcinoma (MTC) occurs in hereditary and sporadic forms in a 1:3 ratio. Germline mutations in RET, a receptor tyrosine kinase expressed in neural crest derivatives, cause the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). [1] [2] [3] Somatic RET mutations have been found in sporadic MTC. 4 -6 Approximately 25% to 80% of sporadic MTCs have been found to harbor somatic mutations. 7 However, mutation analysis in subpopulations of sporadic MTC has shown that these somatic mutations are heterogeneously present. 8 This may suggest that RET mutations occur during tumor evolution rather than being the initial step. A rare germline polymorphism in exon 14 (S836S) has been found to be over-represented in patients with sporadic MTC when compared to control groups. 9, 10 In general, while somatic missense mutations in RET are found in sporadic MTC, translocations or inversions involving RET are found in another type of thyroid carcinoma, papillary thyroid carcinoma (PTC). [11] [12] [13] Similar to RET, another tyrosine kinase receptor, NTRK1, also known as TRKA, is involved in the pathogenesis of PTC. 11, 14, 15 Because of similarities in the involvement of the 2 tyrosine kinases RET and TRKA in the pathogenesis of PTC and the parallels between RET and NTRK1 and between PTC and MTC, as noted above, NTRK1 appeared to be an excellent candidate gene to play a role in the genesis of MTC. Mutation analysis, however, did not reveal any non-polymorphic sequence variants. 10 In agreement with this finding, immunohistochemical analysis instead suggested a role for NTRK2 (also known as TRKB 16 ) and NTRK3 (also known as TRKC 17 ), which are also neurotrophin receptors, in the pathogenesis of MTC. 17 In advanced stages of MTC, NTRK2 expression was substantially reduced compared to NTRK3 expression, which was increased. 17 Therefore, we sought to determine whether mutations in NTRK2 and NTRK3 account for the observed difference in protein expression in MTC.
MATERIAL AND METHODS

Patients and specimens
A series of 31 German patients diagnosed with sporadic MTC was ascertained. Patients were classified as having sporadic MTC when no germline mutations could be identified in the RET protooncogene. 10 In addition, there was no family history of MTC, pheochromocytoma or parathyroid disease. At operation, tumor tissue and corresponding peripheral blood samples were obtained from all patients and flash frozen in liquid nitrogen. All samples were obtained with informed consent.
Peripheral blood was obtained from a population-matched, geographically matched control group. This ethnicity-matched control group consisted of patients who were admitted to the Department of General Surgery, Martin-Luther-Universität Halle-Wittenberg (Halle, Germany), for non-MTC-related diseases. Informed consent was given in all cases.
DNA extraction
Genomic DNA from flash-frozen tissue and blood DNA were extracted using the QIAamp Tissue Kit (Qiagen, Santa Clarita, CA) according to the manufacturer's instructions.
Genomic structure and intron-exon boundaries in NTRK2
To determine the genomic structure of NTRK2, we performed long-range PCR using the LA PCR Kit (Takara Shuzo, Kyoto, Japan) according to the manufacturer's instructions. Briefly, PCR amplification was carried out in 1ϫ PCR buffer (Takara Shuzo) containing 1.5 mM MgCl 2 , 200 mol/l dNTP, 0.4 mol/l of each primer, 2.5 U Taq polymerase (Takara Shuzo) and 100 to 200 ng of genomic DNA template in a 50 l volume. Primers were chosen assuming that the positions of exon-intron boundaries are conserved among the 3 Trk genes. Forward and reverse primers to delineate the NTRK2 genomic structure were selected based on these predicted boundaries, using the reference cDNA sequence of Nakagawara et al. 16 (accession number U12140). PCR conditions were as follows: 1 cycle of 2 min at 94°C; 35 cycles of 20 sec at 98°C, 30 sec at 60°C, 15 min at 68°C; followed by 1 cycle of 10 min at 72°C. PCR product was subjected to electrophoresis through a 1% low-melt agarose gel and visualized by UV transillumination after ethidium bromide staining. The most distinctly visualized bands were subjected to purification using the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer's recommendations and semi-automated sequencing using the both forward and reverse primers and dye terminator technology, as previously described. 18 We also chose BAC library screening as another approach to obtain intronic sequences. Four PCR-generated, radiolabeled probes (Prime-It II Random Primer Labeling Kit; Stratagene, La Jolla, CA) containing sequences within the human NTRK2 cDNA were used to hybridize against the 12ϫ coverage human BAC library (RPCI-11). For BAC library screening, the 2 5Ј-end probes and the 2 3Ј-end probes were pooled.
While we were screening our BAC libraries, a working draft of human chromosome 9 became available on the Internet. This working draft covered all exons but exon 9 of NTRK2. Finally, to obtain the intronic sequence around exon 9, we used the Vectorette System (Sigma, The Woodlands, TX) according to the manufacturer's instructions. In brief, genomic DNA was digested with HindIII, TaqI and EcoRI and subsequently ligated to a Vectorette unit. PCR using 1 primer directed at the Vectorette unit and 1 primer within that specific exon was performed. PCR product was visualized, purified and sequenced as described above.
PCR, mutation analysis, SSCP
Mutation analysis was performed using a combination of singlestrand conformational polymorphism (SSCP) and direct sequencing. Primers used to amplify exons of NTRK2 were designed according to the sequencing results obtained by long-range PCR, BAC library screening, use of genomic sequences in databases available to the public (http://www.ncbi.nlm.nih.gov/blast/blast.cgi ; database htgs) and Vectorette PCR (Table I ). The genomic structure of NTRK3, including intron-exon boundaries, has been described, 19 and primers to generate amplicons of NTRK3 were designed accordingly (Table IIA) .
PCR amplification was carried out in 1ϫ PCR buffer (Qiagen) containing 1.5 mM MgCl 2 , 200 mol/l dNTP, 0.6 mol/l of both sense and anti-sense primer, 2.5 U Taq polymerase (Qiagen) and 100 to 200 ng of tumor DNA template in a 50 l volume. PCR conditions were as follows: 1 cycle of 15 min at 95°C; 35 cycles of 1 min at 95°C, 1 min at 55°to 58°C (Tables I, II) , 1 min at 72°C; followed by 1 cycle of 10 min at 72°C.
For most exons, mutation analysis was performed using SSCP. For each exon, at least 5 randomly chosen samples were sequenced, to exclude the possibility that sequence variants were missed by SSCP analysis.
Before SSCP, some PCR products (Table IIB) were subjected to further digestion, to obtain smaller fragments, which are more likely to show alternate banding patterns using SSCP. 20 Of the resulting PCR/digestion product, 2 l were added to 3 l of formamide buffer, then heated to 95°C for 10 min and subsequently cooled on ice. Samples were subjected to electrophoresis through polyacrylamide/Tris-borate-EDTA gels (Table IIB) . Subsequent silver staining was done as previously described. 10 If 5Ј-TTTTAGAAGCAGCGATCGGA-3Ј  326  TRKC-1R  5Ј-CAGGAGGGAGACGCAGAG-3Ј  2  TRKC-2F  5Ј-TCTGGCTGACCGTTACCTTT-3Ј  239  TRKC-2R  5Ј-AAAAGAAGACCTGGGGGAGA-3Ј  3  TRKC-3F  5Ј-GAGCAGATATCCCTCTGCCA-3Ј  189  TRKC-3R  5Ј-TTCACTGCCCCAAGAGTACC-3Ј  4  TRKC-4F  5Ј-GCATTATTTGTGCCAGACTTG-3Ј  208  TRKC-4R  5Ј-AGGTGGTTCCACTGCTTGAC-3Ј  5 TRKC-5F 5Ј-TCCCTTCCCCTCTCTCTTTG-3Ј 248 SSCP revealed a different banding pattern, the remaining PCR aliquot was subjected to purification and semi-automated sequencing as described above.
Statistical analysis
Each locus had 2 alleles or 2 chromosomes, so each case or tumor is comprised of 2 chromosomes or alleles at each polymorphic locus. For the statistical analysis, each allele at each locus was counted. Thus, for a total of 31 MTC cases, 62 total chromosomes or alleles are involved per locus.
Frequencies of polymorphic allelic variants were compared using the 2 statistic or Fisher's exact test, as previously employed. 10 A 2-tailed p Ͻ 0.05 was considered significant.
RESULTS
Genomic structure of NTRK2
As a result of long-range PCR followed by sequencing, BAC library screening and vectorette PCR, we found that NTRK2 spans 17 exons varying in size from 36 to 306 bp (Fig. 1) . Two out of several clones obtained by BAC screening, clone 11E18 (AC013261) obtained using the 5Ј probe and clone 700N14 (no accession number) obtained using the 3Ј probe, were subjected to sequence analysis. Clone 11E18 contained exons 1-5 of NTRK2 and clone 700N14 contained exons 12-17 of NTRK2. Four other BAC clones in addition to these 2 contained all exons (the authors may be contacted for further details of exon coverage by these BACs).
Mutation analysis
SSCP analysis and direct sequencing of all 17 exons of NTRK2 from 31 sporadic MTCs did not reveal any sequence variants. SSCP analysis of all 18 exons of NTRK3 from 31 sporadic MTCs revealed variants in 3 exons (exons 5, 6 and 12; Fig. 2 ). Sequencing demonstrated 1 variant in each exon, c.573CϾT (N191N), c.678TϾC (N226N) and c.1488CϾG (A496A) occurring in 31% (19 chromosomes), 2% (1 chromosome) and 39% (24 chromosomes) out of a total of 62 case chromosomes, respectively. Corresponding germline DNA was examined for the presence of each of these variants, and all were also present in the germline. There was a trend toward excess association of the NTRK3 variant c.1488CϾG (A496A) in cases (24/62 chromosomes, 39%) compared to controls (18/62, 29%) , but this did not reach statistical significance ( p Ͼ 0.05). The remaining 2 NTRK3 variants occurred with similar frequencies between MTC cases and populationmatched controls (19 vs. 17 and 1 vs. 0, p Ͼ 0.05) .
DISCUSSION
In the present study, we determined the genomic structure of NTRK2 and detected 3 novel sequence variants in NTRK3. We also determined the frequency of these sequence variants in patients with sporadic MTC and a matched control group.
McGregor et al. 17 examined the role of the Trk receptor tyrosine kinase family of neurotrophin receptors in MTC. They found that only a subset of normal C cells expresses Trk family receptors but that C-cell hyperplasias consistently express NTRK2, with variable expression of NTRK1 and NTRK3. In later stages of macroscopic MTC tumors, NTRK2 expression was clearly reduced, while NTRK3 expression was increased and often intense. In a previous study, we showed that somatic mutations in NTRK1 are not common in sporadic MTCs. 10 In the present study, we did not find any somatic mutations of NTRK2 and NTRK3 in tumor DNA from 31 independent patients with sporadic MTC. Hence, we conclude that sequence variants in these genes are not likely to be responsible for differences in expression at the protein level, as previously reported. 17 Hence, some other mechanism must be found to explain the reduced expression of NTRK2 and the increased expression of NTRK3. BDNF, one of the ligands of NTRK2, down-regulated NTRK2 protein levels in cultured rat neuronal cell lines. 21, 22 Whether the same mechanism is responsible for down-regulation of NTRK2 in advanced stages of MTC remains to be shown. Also of note, analyses of lymphocytes suggest that NTRK3 increases (speeds) progression through the cell cycle without affecting cell survival. 23 Therefore, increased expression of NTRK3 may have the same effect in later stages of MTC.
Although we did not find any somatic mutations of NTRK2 or NTRK3 in sporadic MTC or an association with sequence variants in this relatively small number of cases, the genomic structure of NTRK2, the SSCP conditions reported here and the knowledge of the frequency of various sequence variants may help in future mutation analyses of DNA from other neural and non-neural tissues that express NTRK2 or NTRK3. 23, 24 It is our hope that independent studies of the TRK family in larger series will identify these as low-penetrance modifiers of sporadic MTC risk. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation The aetiology of sporadic medullary thyroid carcinoma is unknown. About 50% harbour a somatic mutation at codon 918 of RET (M918T). To investigate whether other RET sequence variants may be associated with or predispose to the development of sporadic medullary thyroid carcinoma, we analysed genomic DNA from the germline and corresponding tumour from 50 patients to identify RET sequence variants. In one patient, tumour DNA showed a novel somatic 12 bp in-frame deletion in exon 15. More interestingly, we found that the rare polymorphism at codon 836 (c.2439C4T; S836S) occurred at a signi®cantly higher frequency than that in control individuals without sporadic medullary thyroid carcinoma (Fisher's exact test, P=0.03). Further, among the nine evaluable cases with germline c.2439C/T, eight also had the somatic M918T mutation in MTC DNA which was more frequent than in patients with the more common c.2439C/C (89% vs 40%, respectively; Fisher's exact test, P=0.01). These ®ndings suggest that the rare sequence variant at codon 836 may somehow play a role in the genesis of sporadic medullary thyroid carcinoma.
Keywords: tyrosine kinase; polymorphism; germline mutation; somatic mutation; medullary thyroid cancer Medullary thyroid carcinoma (MTC) comprises approximately 5 ± 10% of all thyroid malignancies (Bergholm et al., 1990) . About 75% of all MTCs are believed to be sporadic (Bergholm et al., 1990; Raue et al., 1993) , and the remaining 25% comprise the autosomal dominant multiple endocrine neoplasia type 2 (MEN 2) syndromes, MEN 2A, MEN 2B and familial MTC (Farndon et al., 1986; Schimke, 1984) . Germline mutations of the RET protooncogene aecting exons 10, 11, 13, 14, 15 and 16 have been found to be associated with MEN 2 (Bolino et al., 1995; Carlson et al., 1994; Donis-Keller et al., 1993; Eng et al., 1994 Eng et al., , 1995 Farndon et al., 1986; Gimm et al., 1997; Hofstra et al., 1994; Schimke, 1984; Smith et al., 1997) . Speci®cally, germline mutation at codon 918 (M918T) in exon 16 is associated with 495% of MEN 2B , which is characterized by a more severe form of MTC and phaeochromocytoma occurring at a young age and classic stigmata such as ganglioneuromatosis and a marfanoid habitus. Functional, biochemical and limited animal modelling studies have demonstrated that the RET mutations which characterize MEN 2 are capable of activation, sometimes in a constitutive manner, of the RET signalling pathway (Borrello et al., 1995; Ceccherini et al., 1997; Michiels et al., 1997; Pasini et al., 1997; Santoro et al., 1995) . The MEN 2B-type mutation, M918T, has been shown to alter substrate speci®city (Borrello et al., 1995; Santoro et al., 1995; Songyang et al., 1995) . Interestingly, a median of 50% of sporadic MTC harbour somatic M918T mutations . Despite our rapidly accumulating knowledge of the genetics and biochemistry of RET, it is not really known how M918T occurs. Further, while a number of the MEN 2-and MTC-associated RET mutations have been shown to be functionally signi®cant, it is not known whether neutral sequence variants play other interacting, predisposing or modifying roles in the pathogenesis of MEN 2 or sporadic MEN 2-related tumours.
In this study, we analysed paired somatic and germline DNA from 50 sporadic MTC cases (German origin 38, US origin 12) to determine the frequency of somatic M918T and the frequency of other RET sequence variants in the germline of individuals versus race-matched, region-matched control individuals. Patients were classi®ed as having sporadic MTC when no MEN 2-speci®c germline RET mutations could be identi®ed. Clinically, none of the cases had family histories of MTC, phaeochromocytoma or parathyroid disease.
MTC tumour specimens were obtained from each of 36 patients and¯ash frozen in liquid nitrogen. In the remaining 14 patients, MTC samples were paranembedded. All samples were obtained with informed consent. Blood and tumour DNA were extracted using the QIAamp tissue kit according to the manufacturer's instructions (Qiagen, Santa Clarita, CA, USA).
To screen for the presence of somatic M918T in each of these tumours, exon 16 amplicons were prepared using either fRET16 and rRET16 (Hofstra et al., 1994) or CRT5H and CRT5G and PCR conditions as previously described. An additional second-round PCR using identical conditions was performed using primers designed to introduce a RsaI restriction site in the presence of the codon M918T mutation . Overnight digestion of the f16Rsa-generated exon 16 amplicon was then performed with an excess of the restriction endonuclease RsaI (New England Biolabs, Inc., Beverly, MA, USA). Additionally, overnight digestion of the f16Rsa-generated PCR product was also performed with an excess of the restriction endonuclease Sau3AI as a control for digestion. Of 50 sporadic MTCs, 25 (50%) were found to have somatic M918T, a frequency similar to that reported in the literature In an attempt to search for additional somatic mutations in these MTC, PCR amplicons of exons 13 ± 15 were subjected to direct sequencing. We did detect a somatic 12-bp deletion in exon 15, which was absent in the germline. This novel mutation, c.2622/3/4/5-2633/4/ 5/6del12 (because of repetitive sequences, it was impossible to determine which of four possible combinations of 12 nucleotides had been deleted) results in a 4-amino acid in-frame deletion (RDVYEE to RE).
We next turned our attention to examining the frequency of seven known RET sequence variants/ polymorphisms in the germline of the 50 sporadic MTC patients and comparing them to that in race-and region-matched normal controls. The frequencies of both alleles at six of the seven polymorphic sites were similar in cases and controls (Table 1) . Of interest, we found an over-representation of a rare sequence variant, c.2439C4T/S836S (exon 14), in the germline of patients with sporadic MTC (Table 1) . In one case, neither sequence analysis nor restriction analysis could clearly delineate the presence or absence of the c.2439C4T sequence variant in the germline despite multiple repetitions. Therefore, this case was excluded for the purpose of statistical analyses. Of 49 evaluable patients, nine had the heterozygous germline sequence variant c.2439C4T (9%, i.e. 9T:89C). Analysis of 140 chromosomes from 70 race-matched, region-matched control patients (German origin 50, US origin 20) demonstrated the presence of the T sequence variant in 5 (3.6%) alleles (data not shown). The 3.6% allele frequency in our controls is similar to the 3.7% in 188 French alleles reported in the literature (Rodien et al., 1997) . Therefore, the 9% T allele frequency in our cohort of MTC patients is signi®cantly higher than that occurring in controls without MTC (Fisher's exact test, P=0.03). Further, eight of those nine patients who carried the rare sequence variant at codon 836 (c.2439C4T) also had tumours with somatic M918T mutation (c.2684T4C). The association of the c.2439C4T sequence variant and the presence of somatic M918T in corresponding tumours is also statistically signi®cant (Table 2, Fisher's exact test, P=0.01).
To determine whether the c.2439T variant lies on the same allele as the M918T mutation, we used genomic DNA extracted from seven¯ash frozen tumours and , except for primers used to amplify exon 3: f3-Sau3AI (5'-CTTTCCCCTGCTCACCGTCTACCTCAAGAT-3'), and exon 7: RET-7R (5'-TTGTACTGGACGTTGATGCC-3') performed long distance PCR encompassing RET exons 14, 15 and 16. This analysis could not be done in the remaining two tumours because they were paran-embedded and a fragment of about 2.5 kb could not be ampli®ed. Long distance PCR was performed using 100 ± 200 ng of genomic DNA template, 0.4 mM of primer CRT4N, 0.4 mM of primer M918T-R (5'-AAAAGGGATTCAATTGCCG-3'), and the TaKaRa LA PCR Kit Ver 2 (TaKaRa Shuzo Co., Ltd., Japan): 16 PCR buer, 8 ml of dNTP, and 0.5 ml LA Taq in a ®nal volume of 50 ml. The PCR was hot started at 948C for 2 min, after which the LA Taq was added, followed by 30 cycles of 20 s at 988C, 30 s at 628C, and 15 min at 688C, and a ®nal extension of 10 min at 728C. The forward primer CRT4N was positioned in intron 13 upstream of codon 836. The novel M918T-R primer was designed such that it would anneal to the template only in the presence of the M918T (c.2684T4C) mutation. Under these PCR conditions, therefore, the primer M918T-R was shown to amplify only the allele carrying the mutation M918T (c.2684T4C). This was a method for selecting for only the allele bearing M918T (Figures 1 and 2a ). Sequence analysis of this long distance amplicon con®rmed the homogenous presence of only the M918T (ACG) allele in all instances (data not shown). Using this allelespeci®c PCR product as template, a second round PCR was performed using the exon 14-speci®c primers CRT4N and CRT4K. This exon 14 amplicon was subjected to AluI digestion. In the presence of the c.2439C wildtype sequence, AluI would digest the amplicon. In contrast, in the presence of the variant (c.2439T) allele, AluI would not digest the amplicon. Of the 7 M918T-speci®c exon 14 amplicons generated, ®ve were not digested by this enzyme and thus contained the c.2439T variant, while two were completely digested and thus, was shown to contain the c.2439C wildtype sequence (Figure 2a ). In summary, the c.2439C4T variant was on the same allele as the M918T mutation in ®ve MTCs while in the remaining two cases, the T variant and the M918T mutation were on opposite alleles. In sum, only the c.2439C4T variant appeared to be over-represented in sporadic MTC cases compared to geographic controls. More interestingly, eight of the nine patients with the C/T variant also had somatic M918T. This variant at codon 836 has been described in the literature with a frequency of 3.7% (Rodien et al., 1997) , which is very similar to the frequency of 3.6% which we found among our 140 control alleles. One could argue that the higher incidence of this sequence variant in patients with MTC in our study is an artefact secondary to small sample size. However, the frequencies of all other sequence polymorphisms noted in our series of MTC patients were similar to those previously reported by others (Ceccherini et al., 1994) . These observations argue strongly against the S836S-M918T association as coincidence due to small sample size and suggest that the association of the germline c.2439C4T variant is somehow related to somatic M918T and the pathogenesis of a subset of sporadic MTC. If the germline c.2439C4T variant is associated with the development of MTC, i.e., a low penetrance allele, then, it may be postulated, without experimental evidence thus far, that some instances of FMTC', especially families which comprise only two aected cases, might be due to the presence of this low penetrance allele and not the classic FMTC mutations. If this was true, such`small' FMTC families should have germline S836S, no typical MEN 2 type mutation, and the MTC tumour should have somatic M918T. Anecdotally, one FMTC family with no classic MEN 2-type RET mutations had the germline c.2439C4T variant which appeared to segregate with disease (Gimm and Eng, unpublished observations) . Obviously, a concerted eort, perhaps by the Interna- Figure 1 Algorithm to determine whether the S836S T variant lies on the same allele as the M918T (ACG) mutation tional RET Mutation Consortium would be needed to prove this postulate with adequate statistical power.
The precise mechanism by which c.2439T and M918T may interact in sporadic MTC genesis is unknown and open to speculation. Since this sequence variant does not lead to an amino acid alteration, S836S, it is dicult to imagine how this conserved polymorphism may aect RET. However, it is conceivable that the sequence variant c.2439T enhances the expression of RET. In this regard, it has been shown that polymorphic sequence variants can lead to production of dierent amounts of mRNA (Leviev et al., 1997) . At the nucleotide level, several possibilities exist. One might hypothesize that the AGC4AGT polymorphism causes the creation of a cryptic splice donor, splice acceptor or splice enhancer, therefore, leading to an altered protein. There is precedent in this regard. For example, alternative splicing of the human growth hormone transcript might be the result of an unusual polymorphism (Stallings-Mann et al., 1996) . Dierential splicing of episialin mRNA has been shown to be dictated by a single exonic nucleotide polymorphism (Ligtenberg et al., 1991) . Further data demonstrate that a splice siteassociated polymorphism in the tuberous sclerosis 2 (TSC2) gene may predispose to the development of sporadic gangliogliomas (Platten et al., 1997) . Similar mechanisms are conceivable in alternative splicing of RET mRNA. Unfortunately, cDNA was not available in our patients and this postulate remains speculative.
The observation of the germline c.2439T variant in both cis and trans with the somatic M918T mutation must also be explained. In ®ve patients, it appears that the somatic M918T mutation occurs on the c.2439T allele rather than in the wildtype allele. In this situation, the c.2439T variant may create an unstable sequence downstream at codon 918, resulting in the somatic M918T mutation instead of directly participating in the tumourigenic process. Such a mechanism has been observed in the APC gene in a fraction (28%) of Ashkenazim with familial colorectal cancer where additional somatic mutations were more often found on that allele carrying a seemingly innocuous germline missense mutation predicted to result in a conservative amino acid change (I1307K) (Laken et al., 1997) . Although a plausible explanation when the c.2439T and M918T variants are on the same allele, this mechanism cannot explain the origin of the somatic M918T mutation in trans with the c.2439T variant in the remaining two patients. Finally, the apparent preference of the M918T mutation to occur on the c.2439T allele might be due to the small sample size.
While our data suggest that a neutral germline sequence variance RET may somehow predispose to sporadic MTC, especially those that harbour somatic M918T, it remains for further largescale molecular epidemiologic studies to determine if this is a phenomenon generalizable to dierent populations and for functional analyses to prove that this variant indeed contributes to the MTC phenotype. the Deutsche Forschungsgemeinschaft (to OG) and a Barr Investigatorship (to CE). CE is the Lawrence and Susan Marx Investigator in Human Cancer Genetics. In contrast to the hereditary form of medullary thyroid carcinoma (MTC), little is known about the etiology of sporadic MTC. Somatic gain-of-function mutations in the RET proto-oncogene, encoding a receptor tyrosine kinase, are found in an average of 40% of sporadic MTC. We analysed 31 sporadic MTC for somatic and germline variants in GFRA1, GFRA2 and GFRA3 which encode the co-receptors of RET. Although there were no somatic mutations in any of the three genes, a sequence variant (7193C4G) in the 5'-UTR of GFRA1 was found in 15% of cases. Three patients were heterozygous (het); another three patients homozygous (hom) for the G variant. The G allele was not observed in 31 racematched normal controls. Hence, the relative frequency of this variant in sporadic MTC cases and controls diered signi®cantly (P50.05). Since this variant lies in the 5' UTR, likely at the transcriptional start site, we analysed for dierential expression of GFRa-1 at the transcript and protein levels. At the mRNA level, GFRA1 was over-expressed in tumors harboring the rare variant (P=0.06). The presence of the G polymorphic allele seemed to be associated with increased expression by immunostaining for GFRa-1. Interestingly, cytoplasmic staining was stronger in intensity for het patients and nuclear staining predominant in hom cases.
In conclusion, mutation analysis of GFRA1, GFRA2 and GFRA3 revealed over-representation of a rare variant in GFRA1 (7193C4G) in the germline of sporadic MTC cases. Our data suggest that the mechanism is related to over-expression of GFRa-1 and dierential subcellular compartmentalization but the precise mechanism as toIntroduction Medullary thyroid carcinoma (MTC) accounts for 5 ± 10% of all thyroid malignancies. About 25% are hereditary, the etiology of which is well known. Germline gain-of-function mutations in the RET proto-oncogene, encoding a receptor tyrosine kinase (Takahashi and Cooper, 1987) , cause the inherited multiple endocrine neoplasia type 2 (MEN 2) syndromes, MEN 2A, MEN 2B and familial MTC (Carlson et al., 1994; Donis-Keller et al., 1993; Eng et al., 1994 Eng et al., , 1996a Hofstra et al., 1994; . As of 1996, germline RET mutations have been described in 92% of all MTC with a hereditary background (Eng et al., 1996a) . Further work in the intervening 4 years suggest that495% of all MEN 2 have demonstrable germline RET mutations. In contrast, little is known about the etiology of the majority (75%) of all MTC, which are sporadic. Depending on the method used and perhaps the region of origin, somatic RET mutations, predominantly M918T, are found in about 30 ± 70% of sporadic MTC . However, mutation analysis in subpopulations of sporadic MTC showed that these somatic mutations are heterogeneously present (Eng et al., 1996b) . It was, therefore, postulated that they might occur during tumor evolution rather than being the initiating step. A rare sequence variant in exon 14 (S836S) has been found to be over-represented in patients with sporadic MTC when compared to geographically matched control groups Gimm et al., 1999c ). The precise mechanism remains to be elucidated.
Physiologic RET activation requires binding with ligand and co-receptor. One of four related ligands, GDNF, NTN, PSP, and ART, needs to interact with one of four glycosyl-phosphoinositol (GPI)-linked coreceptors, GFRa-1, GFRa-2, GFRa-3 and GFRa-4, before the heterotetrameric complex can bind RET Durbec et al., 1996; Enokido et al., 1998; Jing et al., 1996 Jing et al., , 1997 Kotzbauer et al., 1996; Milbrandt et al., 1998; Thompson et al., 1998; Trupp et al., 1996) . Recently, another ligand, Enovin (EVN), was described but EVN is identical to ART (Masure et al., 1999) . While each ligand preferentially binds to one co-receptor, low anity interactions with other coreceptors has also been noted for some ligands in vitro Enokido et al., 1998; Jing et al., 1997; Klein et al., 1997; Milbrandt et al., 1998; Sanicola et al., 1997; Trupp et al., 1998) . Activation of RET in this manner plays a signi®cant role during human development (Sanchez et al., 1996; Schuchardt et al., 1994) but may also be important during adulthood (Masure et al., 1999) . There is also growing evidence that RET, each of the ligands and each of the co-receptors are dierentially expressed in a tissuespeci®c and time-speci®c manner (Airaksinen et al., 1999; Baloh et al., 2000; Jing et al., 1997; Masure et al., 1999; Naveilhan et al., 1998; Sanicola et al., 1997) .
If gain-of-function RET mutations are associated with human MTC, then it is equally plausible that mutations in the gene encoding one of the human coreceptor homologues, GFRa-1, GFRa-2 or GFRa-3, could play a role in the pathogenesis of MTC. Hence, we sought to examine the presence of high penetrance somatic mutations or low penetrance germline variants in the genes encoding the three human co-receptors in sporadic MTC.
Results
Mutation analysis of GFRA1, GFRA2 and GFRA3
Mutation analysis of all coding exons and¯anking intronic sequences of GFRA1, GFRA2 and GFRA3 of genomic DNA from 31 sporadic MTC tumors revealed six variants in GFRA1, one variant in GFRA2 and two variants in GFRA3 (Table 3 ; Figure 1 ). Corresponding germline DNA was examined for the presence of each of these variants, and all were also present in the germline. The frequencies of two variants in GFRA1 diered signi®cantly from those in a race-matched control group (Table 1) . The variant c.537C4T (N179N; exon 4) was under-represented in sporadic MTC when compared to the normal controls (P50.05). We analysed whether this sequence variant correlates with the presence of an alternatively spliced exon between exon 3 and exon 4 (Myers et al., 1999) but did not con®rm this hypothesis (data not shown). The other sequence variant (7193C4G) lies in the 5'UTR likely at or near to the transcriptional start site. This sequence variant is normally very rare (Myers et al., 1999) and was not found among 62 race-matched control alleles in this study. In contrast, among 62 MTC alleles, nine carried the polymorphic G allele at nucleotide 7193. Thus, this G variant was heterozygously present in three patients and homozygously present in another three patients with sporadic MTC (Table 2, P50.05).
GFRA1 expression analyses
Because we felt that the C/G variation at 7193 might aect transcription, we performed semi-quantitative duplex PCR comparing GFRA1 to the housekeeping gene GPI to analyse whether any correlation exists between GFRA1 mRNA levels and the sequence at position 7193 (Figure 2) . GFRA1 expression at the mRNA level was seen in all 10 tumors that had RNA available. Interestingly, the heterozygous presence of the rare sequence variant 7193C4G seemed to be an associative trend with higher GFRA1 transcript levels (P=0.06). Unfortunately, no cDNA was available from those three patients with homozygous 7193G/ G variant.
We then analysed the expression of GFRa-1 at the protein level by immunohistochemistry (Table 2, Gimm et al., 1999a; Myers et al., 1999; Onochie et al., 2000) . n.r., not reported; n.s., not signi®cant; MTC, medullary thyroid carcinoma a GFRA1 compared to GPI mRNA levels (see also Figure 3 ). Results have been published (S836S is germline, M918T is somatic) (Gimm et al., 1999c) Oncogene Over-representation of GFRa-1 variant with sporadic MTC O Gimm et al Figure 3 ). Overall, in agreement with the GFRA1 mRNA levels, at least weak expression of GFRa-1 protein was noted in all tumors. Generally, cytoplasmic staining was weak to moderate while nuclear staining varied from weak to strong (Table 2) . Interestingly, tumors from all three patients with homozygous 7193G/G showed strong nuclear staining intensity while cytoplasmic staining intensity was weak to moderate (Figure 3a ± c) . The histopathologic appearance of these three tumors was remarkable in that there were many apoptotic cells present, perhaps indicating a fast-growing tumor. The three tumors with heterozygous 7193C/G showed moderate cytoplasmic staining intensity (Figure 3d ± f) . Apoptotic cells were only seen occasionally. In contrast, most tumors with the wild-type 7193C/C showed rather weak GFRa-1 staining (Figure 3g ± i) . However, there were a few exceptions (Table 2) , i.e. tumors wild-type at position 7193 (C/C) and moderate or strong cytoplasmic and/or nuclear staining (Figure 3k ± m) . Apoptotic cells were rarely observed among tumors with the wild-type 7193C/C. GFRa-1 expression was not associated with the presence of any of the other polymorphic sequence variants in GFRA1, GFRA2, and GFRA3 (data not shown). As shown in Table 2 , GFRA1 expression neither correlated with the presence of the somatic M918T mutation nor the germline S836S sequence variant. However, among the 25 tumors wild-type at position 7193 in GFRA1, two tumors (Patient #6 and #18, Table 2 and Figure 3l ) showed strong cytoplasmic and three others (Patient #10, #17, #20) strong nuclear staining intensity for GFRa-1, patterns normally seen in the presence of the 7193 variant. All these ®ve tumors harbored the wild-type sequence at codons 836 and 918 of RET. In contrast, the status at codons 836 and 918 were random among the six cases with either 7193G/G or 7193C/G.
Discussion
In this study, we have demonstrated absence of somatic mutations in GFRA1, GFRA2 and GFRA3 in a series of sporadic MTC, but we have found two germline sequence variants in GFRA1 which diered in frequency between sporadic MTC cases and matched normal controls. One variant c.573T4C was located in exon 4 and under-represented in sporadic MTC cases, as compared to controls. Interestingly, the frequency of this variant in our control group (55%) was higher than the frequency reported in the literature (40 ± 46%), although the values from the literature were derived from a Canadian control group as well as from Germans with brain tumors. Thus, in this Germanbased case-control comparison, the dierence in variant frequency between the MTC (35%) and controls (55%) is signi®cant (P50.05). Why underrepresentation of this polymorphic allele, which does not alter the amino acid and does not alter splicing, is associated with sporadic MTC is unclear, although linkage disequilibrium with other loci is a plausible explanation.
Even more striking was the over-representation of a rare sequence variant at position 7193 in GFRA1 in sporadic MTC, especially since three patients were homozygous for this sequence variant and we did not ®nd this variant in any of 62 control alleles. The dierence was signi®cant, whether we compared genotypes or alleles. Of note, the 7193C4G variant Figure 2 Ethidium-bromide stained agaros gel of duplex RT ± PCR products. GFRA1 and a housekeeping gene, GPI, were coampli®ed from DNA extracted from each of 10 sporadic MTC. GFRA1 mRNA levels were higher (mean 0.7025) in cases with the 7193C/G sequence variant versus those with wild-type 7193C/C (mean 0.4869) when compared to the housekeeping gene GPI (P=0.065, one-tailed t-test); *NA, see Table 2 Over-representation of GFRa-1 variant with sporadic MTC O Gimm et al was always either heterozygously or homozygously present in both germline and tumor DNA. Hence, it is unlikely that GFRA1 functions as a tumor suppressor gene in this situation; further, LOH on 10q26 has not been reported in MTC. Because the presence or absence of the GFRA1 7193 variant was randomly associated with the presence or absence of the RET S836S variant and the presence or absence of somatic RET M918T, it suggests that the 7193 variant might be a low penetrance allele, independent of RET, associated with sporadic MTC risk. Because 7193 lies in the 5'UTR, likely at or around the transcriptional start site, and perhaps even within the promoter, a variation in that region associated with sporadic MTC risk is interesting and might suggest the mechanism of the association. In agreement with our hypothesis, overall, we observed that the presence of the sequence variant 7193C4G was associated with higher GFRA1 transcript levels. Immunohistochemistry further supported this impression. By immunohistochemistry, it would appear that either the heterozygous or homozygous presence of the polymorphic G allele was associated with increased expression compared to tumors that are wild-type at 7193, although the former had predominant cytoplasmic expression and the latter nuclear. Of interest, tumors with the homozygous sequence variant (7193G/G) showed strong GFRa-1 immunoreactivity accompanied by increased numbers of apoptotic cells, which is usually associated with rapidly growing tumors. Our data also suggest that the 7193 variant status alone is not the only modulator of high GFRa-1 expression as a few tumors without the G variant were found to express GFRa-1 as well: other mechanisms must exist that in¯uence the level of GFRA1 transcription and subsequent translation in sporadic MTC.
The functional meaning of the overall higher levels of GFRa-1 associated with the presence of the 7193G allele is not obvious. It is conceivable that, in the presence of appropriate ligands (e.g. GDNF, NTN), higher levels of GFRa-1 may lead to increased interaction with and subsequent activation of RET. Because GFRa-1 not only interacts with its major ligand GDNF but it can also interact with lower anity with NTN and ART Jing et al., 1997) , it is possible that increased GFRa-1 expression could mean further activation of RET via ligands other than GDNF. GFRa-1, like many GPI-linked membrane-bound proteins, form into complexes around lipid rafts at the membrane and has recently been shown to recruit RET to these lipid rafts after GDNF binding, followed by increased RET phosphorylation and increased Src-RET interaction. Increased GFRa-1 expression in the presence of the GFRA1 7193 variant would be predicted to lead to increased numbers of such complexes at the lipid rafts and hence, increased recruitment of RET to them with subsequent increased signaling. Although controversial, it has been described that GFRa-1 can signal down a pathway independent of RET and its ligands (Trupp et al., 1998) . Thus, increased levels of this co-receptor would increase signaling down this other pathway as well. All these postulates do not contradict our observation of increased apoptotic cells associated with more rapidly growing tumors in the individuals with the G/G genotype at position 7193.
Despite the location of 7193 in the 5'UTR/ promoter region with all its functional implications, it is also equally plausible that the variant 7193C4G may be in linkage disequilibrium with another locus which directly contributes to low penetrance susceptibility to sporadic MTC; such a locus would most likely lie upstream of GFRA1. In summary, mutation analysis of GFRA1, GFRA2 and GFRA3 revealed overrepresentation of an upstream variant in GFRA1 7193C4G as well as under-representation of GFRA1 variant c.573T4C in sporadic MTC cases compared to matched controls. The GFRA1 7193 variant might lend low level susceptibility to sporadic MTC by a mechanism related to increased expression, as suggested by our data. However, the precise mechanisms for both these variants and how they can act as low penetrance susceptibility loci for the development of sporadic MTC remains to be elucidated. To date, therefore, we have shown that both RET and GFRA1 and/or loci in proximity to them might represent low penetrance susceptibility genes for sporadic MTC with relative risks ranging from 2 to 7 (Gimm et al., 1999c and this study).
Materials and methods
Patients and specimens
A series of 31 German patients diagnosed with sporadic MTC was accrued after informed consent was given. Patients were classi®ed as having sporadic MTC when no germline mutations could be identi®ed in the RET proto-oncogene (Gimm et al., 1999c) . In addition, there was no family history of MTC, pheochromocytoma or parathyroid disease. At operation, tumor tissue and corresponding peripheral blood samples were obtained from each patient. A piece of the tumor, which macroscopically appeared to be free of normal tissue, was excised and¯ash frozen in liquid nitrogen for all patients. The remaining tissue was ®xed by immersion in 10% buered formalin for histopathological analysis.
Peripheral blood was obtained from a race-matched control group, with their informed consent. This control group consisted of patients who were admitted to the Department of General Surgery, Halle, Germany, for nonthyroid-related diseases.
DNA extraction
Genomic DNA from¯ash frozen tissue and peripheral blood leucocytes was extracted using the QIAamp Tissue Kit (Qiagen, Santa Clarita, CA, USA) according to the manufacturer's instructions.
Genomic structure and intron-exon boundaries in GFRA2
The genomic structure of GFRA1 and GFRA3 including the intron-exon boundaries have been previously described (Angrist et al., 1998; Myers et al., 1999; Onochie et al., 2000) . The genomic structure of GFRA2 had to be determined and is described in detail elsewhere (Mulligan et al., in preparation) .
PCR-based mutation analysis
Primers and PCR conditions used to amplify exons of GFRA1 have been previously described (Gimm et al., 1999a) . Primers to generate amplicons of GFRA2 were designed according to the sequences obtained from long range and Vectorette PCR (Table 3 ). The human GFRA3 locus has recently been described (Onochie et al., 2000) and primers to generate amplicons of GFRA3 were designed accordingly (Table 3) . PCR ampli®cation was carried out in 16 PCR buer (Qiagen) containing 1.5 mM MgC1 2 , 200 mmol/l dNTP, 0.6 mmol/l of both sense and antisense primer, 2.5 U Taq
Over-representation of GFRa-1 variant with sporadic MTC O Gimm et al polymerase (Qiagen), and 100 ± 200 ng or tumor DNA template in a 50 ml volume. PCR conditions were: one cycle of 15 min at 958C, 35 cycles of 1 min at 958C, 1 min at 58-628C (Table 3) , and 1 min at 728C, followed by one cycle of 10 min at 728C. Mutation analysis was performed using a combination of single-strand conformational polymorphism analysis (SSCP) and direct sequencing (Table 4) . For each exon, at least three randomly chosen samples were sequenced to exclude the possibility that sequence variants were missed by SSCP. No optimal SSCP conditions were found for exon 1 of GFRA1 and GFRA2. Instead, mutation analysis was performed by direct sequencing.
Before SSCP, some PCR products (Table 4) were subjected to further digestion to obtain smaller fragments that are believed to be more likely to reveal variant patterns using SSCP . Two microliters of the resulting PCR/digestion product were added to 3 ml of formamide buer, then heated to 958C for 10 min, and subsequently cooled on ice. The samples were subjected to electrophoresis through polyacrylamide/Tris-Borate-EDTA gels (Table 4) . Subsequent silver staining was done as previously described (Gimm et al., 1999b) . If SSCP revealed a dierent banding pattern, the remaining PCR aliquot was subjected to puri®cation and semi-automated sequencing as described (Gimm et al., 1997) .
RNA extraction and expression analysis of GFRA1
To analyse whether the presence of the rare sequence variant 7193C4G in¯uences expression of GFRA1 at the mRNA level, we extracted RNA from 10 tumors using TRIzol reagent (Life Technologies, Rockville, MD, USA) according to the manufacturer's instructions. RT ± PCR was performed using the 1st Strand cDNA Synthesis Kit (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. To determine the expression level of GFRA1 at the mRNA level, 1 m1 cDNA was used in a duplex PCR containing 1.2 mmol/l each of intron-spanning GFRA1 primers (5'-GA-TATATTCCGGGTGGTCCC-3'; 5'-AAACAGTTGGGCT-TCTCCCT-3') and 0.2 mmol/l each of primers for the housekeeping gene glucosyl-phosphatidylinositol (GPI) (5'- GACCCCCAGTTCCAGAAGCTGC-3'; 5'-GCATCACGT-CCTCCGTCACC-3'). PCR conditions were: one cycle of 15 min at 958C, 30 cycles of 45 s at 958C, 30 s at 588C, 15 s at 728C, followed by one cycle of 10 min at 728C. The PCR product was then subjected to electrophoresis through a 2% agarose gel and visualized by UV transillumination after ethidium bromide staining. The intensity of the PCR products was measured using ImageQuant (Molecular Dynamics, Sunnyvale, CA, USA).
GFRa-1 immunohistochemistry
To analyse the expression of GFRa-1 at the protein level, we performed immunohistochemistry. Four-micron sections of paran-embedded, formalin-®xed tissue were cut, mounted on Superfrost plus slides and baked for 2 h at 608C.
Immunostaining was performed as previously described (Gimm et al., 2000) except using a primary goat polyclonal antibody raised against GFRa-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The speci®city of this antibody has been previously reported. In brief, sections were deparanized and rehydrated by passing through xylene and a graded series of ethanol solutions. Antigen retrieval was performed by boiling at 988C in 0.01 M sodium citrate buer pH 6.4 in a microwave oven for 20 min. In order to block endogenous peroxidase activity, the sections were incubated with 1% hydrogen peroxide in PBS for 30 min after cooling to room temperature. After blocking for 30 min in 0.75% horse serum, the sections were incubated overnight at 48C with a primary goat polyclonal antibody against GFRa-1 (Santa Cruz Biotechnology) at a dilution of 1 : 200. Primary antibody binding was localized by using an avidin-biotinperoxidase kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instruction. The chromogenic reaction was carried out with 0.05% 3,3' diaminobenzidine (Sigma, St. Louis, MO, USA) using nickel cobalt ampli®cation, which gives a black product. Following counterstaining with Nuclear Fast Red (Rowley Biochemical Institute, Danvers, MA, USA) and mounting, the slides were evaluated under a light microscope. Intensity of staining was classi®ed separately for the nucleus and the cytoplasm and graded strong (+++), moderate (++), weak (+) or absent (7) .
RET sequence variants and GFRa-1 expression Germline S836S and somatic M918T sequence variants have been found to be associated with MTC. Since the sequence status at those positions in the MTCs analysed here was known (Gimm et al., 1999c) , we analysed by inspection whether they correlated with expression levels of GFRa-1. 
